Neurology®
The most widely read and highly cited peer-reviewed Neurology journal
Quick Search
Advanced Search
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ueda, M.
Right arrow Articles by Katayama, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ueda, M.
Right arrow Articles by Katayama, Y.
Neurology 1999;52:777
© 1999 American Academy of Neurology
Articles

Susceptibility to neuroleptic malignant syndrome in Parkinson’s disease

M. Ueda, MD, M. Hamamoto, MD, H. Nagayama, MD, K. Otsubo, MD, C. Nito, MD, T. Miyazaki, MD, A. Terashi, MD and Y. Katayama, MD

From the Department of Neurology (Drs. Ueda, Hamamoto, Nagayama, and Miyazaki), Tokyo Metropolitan Tama Geriatric Hospital, Higashimurayama-city; and the Division of Neurology (Drs. Ueda, Otsubo, Nito, Terashi, and Katayama), Second Department of Internal Medicine, Nippon Medical School, Bunkyo-ku, Tokyo, Japan.

Address correspondence and reprint requests to Dr. Masayuki Ueda, Division of Neurology, Second Department of Internal Medicine, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan.

OBJECTIVE: To determine susceptibility to neuroleptic malignant syndrome (NMS) in patients with PD in relation to central monoamine metabolism.

METHODS: CSF levels of homovanillic acid (HVA), 3-methoxy-4-hydroxy phenyletilene glycol (MHPG), and 5-hydroxyindole acetic acid (5-HIAA) were assayed in 98 PD patients (mean age, 77.2 years), including 11 patients with a prior NMS-like episode, by high-performance liquid chromatography with electrochemical detection.

RESULTS: Patients with a previous NMS-like episode had worse parkinsonian disability as measured by Hoehn & Yahr scale (3.7 ± 0.8 versus 3.0 ± 1.1; p = 0.038) and lower CSF HVA levels (20.9 ± 17.3 versus 44.7 ± 22.2 ng/mL; p = 0.001) compared to those without, despite similar age, disease duration, and daily dosages of antiparkinsonian drugs between groups. Logistic regression analysis showed that the CSF HVA level (p = 0.008), but not 5-HIAA level (p = 0.621), was significantly and independently related to NMS, and that the MHPG level (p = 0.070) was tendentially associated with the disorder. Odds ratios (95% confidence intervals) corresponding to 10 ng/mL increment in CSF HVA, MHPG, and 5-HIAA levels were 0.30 (0.13 to 0.73), 4.03 (0.89 to 18.2) and 1.29 (0.47 to 3.58), respectively.

CONCLUSIONS: Central dopaminergic and possible noradrenergic activity contributes to NMS development in an elderly population of PD patients. Measuring CSF levels of monoamine metabolites may provide a means for identifying NMS susceptibility in PD patients.




This article has been cited by other articles:


Home page
 NeurologyHome page
M. Onofrj and A. Thomas
Acute akinesia in Parkinson disease
Neurology, April 12, 2005; 64(7): 1162 - 1169.
[Abstract] [Full Text] [PDF]

Home page
 Br J AnaesthHome page
M. Stotz, D. Thummler, M. Schurch, J.-C. Renggli, A. Urwyler, and H. Pargger
Fulminant neuroleptic malignant syndrome after perioperative withdrawal of antiParkinsonian medication
Br. J. Anaesth., December 1, 2004; 93(6): 868 - 871.
[Abstract] [Full Text] [PDF]

Home page
 PsychosomaticsHome page
I. Tofler
Olanzapine and Neuroleptic Malignant Syndrome
Psychosomatics, December 1, 2002; 43(6): 505 - 506.
[Full Text] [PDF]

Home page
 NeurologyHome page
M. Ihara, N. Kohara, F. Urano, H. Ichinose, S. Takao, T. Nishida, H. Saiki, Y. Kawamoto, A. Ikeda, S. Takagi, et al.
Neuroleptic malignant syndrome with prolonged catatonia in a dopa-responsive dystonia patient
Neurology, October 8, 2002; 59(7): 1102 - 1104.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
J. Jankovic
Levodopa strengths and weaknesses
Neurology, February 1, 2002; 58(90001): S19 - 32.
[Abstract] [Full Text]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
M Ueda, M Hamamoto, H Nagayama, S Okubo, S Amemiya, and Y Katayama
Biochemical alterations during medication withdrawal in Parkinson's disease with and without neuroleptic malignant-like syndrome
J. Neurol. Neurosurg. Psychiatry, July 1, 2001; 71(1): 111 - 113.
[Abstract] [Full Text] [PDF]